Literature DB >> 27282597

Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease.

Zhe Zheng1, Bo Xu2, Heng Zhang1, Changdong Guan2, Ying Xian3, Yanyan Zhao4, Hongyang Fan1, Yuejin Yang2, Wei Wang1, Runlin Gao2, Shengshou Hu5.   

Abstract

OBJECTIVES: This study sought to investigate long-term clinical outcomes following coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) in patients with unprotected left main disease (ULMD).
BACKGROUND: PCI has been increasingly used as an alternative mode of revascularization for ULMD. However, there are limited data comparing clinical outcomes between CABG surgery and PCI.
METHODS: Between 2004 and 2010, 4,046 consecutive patients with ULMD were treated with either CABG surgery (n = 2,604) or PCI (n = 1,442) with drug-eluting stents. The primary outcome was 3-year all-cause mortality and the secondary outcome was the composite of death, nonfatal myocardial infarction, or nonfatal stroke.
RESULTS: The unadjusted 3-year all-cause mortality was higher in the PCI group as compared with the CABG group (3.8% vs. 2.5%; log-rank p = 0.03), although there was no significant difference in the composite outcome (7.5% vs. 9.4%; log-rank p = 0.07). After adjustment for differences in baseline risk factors, PCI was associated with significantly higher risk of all-cause mortality (hazard ratio [HR]: 1.71; 95% confidence interval [CI]: 1.32 to 2.21; p < 0.001) but similar risk of the composite outcome (HR: 0.94; 95% CI: 0.82 to 1.09; p = 0.43). These differences were not statistically significant among patients with low or intermediate SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score (≤32) or diabetes; however, PCI was associated with an increased risk among those with high SYNTAX score (>32), with HRs of 3.10 (95% CI: 1.84 to 5.22; p < 0.001) for all-cause mortality and 1.82 (95% CI: 1.36 to 2.45; p < 0.001) for the composite outcome. CABG was associated with lower risk of repeat revascularization but higher risk of stroke in each clinically relevant subgroup.
CONCLUSIONS: In this single-center observational study among patients with ULMD, CABG was associated with improved long-term outcomes, especially in patients with more complex disease.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary artery bypass surgery; coronary artery disease; percutaneous coronary intervention; unprotected left main disease

Mesh:

Year:  2016        PMID: 27282597     DOI: 10.1016/j.jcin.2016.03.039

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  13 in total

1.  Stent fracture is associated with a higher mortality in patients with type-2 diabetes treated by implantation of a second-generation drug-eluting stent.

Authors:  Zhen Ge; Zhi-Zhong Liu; Jing Kan; Jun-Jie Zhang; Sui-Ji Li; Nai-Liang Tian; Fei Ye; Xue-Song Qian; Song Yang; Meng-Xuan Chen; Tanveer S Rab; Shao-Liang Chen
Journal:  Int J Cardiovasc Imaging       Date:  2017-06-19       Impact factor: 2.357

Review 2.  Cardiac surgery 2016 reviewed.

Authors:  Torsten Doenst; Yasin Essa; Khalil Jacoub; Alexandros Moschovas; David Gonzalez-Lopez; Hristo Kirov; Mahmoud Diab; Steffen Bargenda; Gloria Faerber
Journal:  Clin Res Cardiol       Date:  2017-04-10       Impact factor: 5.460

3.  Informing power and sample size calculations when using inverse probability of treatment weighting using the propensity score.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2021-09-12       Impact factor: 2.497

4.  Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients.

Authors:  Hao-Yu Wang; Dong Yin; Yan-Yan Zhao; Rui Zhang; Yue-Jin Yang; Bo Xu; Ke-Fei Dou
Journal:  J Atheroscler Thromb       Date:  2021-03-20       Impact factor: 4.394

5.  Total revascularization for an epsilon right coronary artery and severe left main disease combined with profound cardiogenic shock: A case report.

Authors:  Hsiu-Yu Fang; Wei-Chieh Lee; Chiung-Jen Wu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

6.  Meta-analysis study comparing percutaneous coronary intervention/drug eluting stent versus coronary artery bypass surgery of unprotected left main coronary artery disease: Clinical outcomes during short-term versus long-term (> 1 year) follow-up.

Authors:  Waleed E Ali; Satyanarayana R Vaidya; Sylvester U Ejeh; Kingsley U Okoroafor
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  Long term outcomes of drug-eluting stent versus coronary artery bypass grafting for left main coronary artery disease: a meta-analysis.

Authors:  Kong-Yong Cui; Shu-Zheng Lyu; Xian-Tao Song; Fei Yuan; Feng Xu; Min Zhang; Ming-Duo Zhang; Wei Wang; Dong-Feng Zhang; Jing Dai; Jin-Fan Tian; Yun-Lu Wang
Journal:  J Geriatr Cardiol       Date:  2018-02       Impact factor: 3.327

8.  Adverse Cardiovascular Outcomes associated with Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention with Everolimus Eluting Stents: A Meta-Analysis.

Authors:  Pravesh Kumar Bundhun; Manish Pursun; Abhishek Rishikesh Teeluck; Akash Bhurtu; Mohammad Zafooruddin Sani Soogund; Wei-Qiang Huang
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

Review 9.  Percutaneous intervention versus coronary artery bypass graft surgery in left main coronary artery stenosis: a systematic review and meta-analysis.

Authors:  Xin-Lin Zhang; Qing-Qing Zhu; Jing-Jing Yang; Yu-Han Chen; Yang Li; Su-Hui Zhu; Jun Xie; Lian Wang; Li-Na Kang; Biao Xu
Journal:  BMC Med       Date:  2017-04-21       Impact factor: 8.775

10.  Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies.

Authors:  ChuanNan Zhai; HongLiang Cong; Kai Hou; YueCheng Hu; JingXia Zhang; YingYi Zhang
Journal:  Diabetol Metab Syndr       Date:  2019-12-19       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.